This will be replaced by the player.

Posts Tagged ‘TEVA’

(TEVA, MJGCF, OPTR, STXS) Stock Report from Drstockpick.com

Wednesday, December 14th, 2011

drstock-2-3

chartstockalert

__

Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) announced that it will host a conference call and live webcast on Wednesday, December 21, 2011 at 8:30 a.m. ET to communicate its 2012 business outlook. A Question & Answer session will follow. In order to participate, please dial the following numbers (at least 10 minutes before the scheduled start time): United States and Canada 866-770-7120; International 1-617-213-8065 and enter passcode 23520783. A live webcast of the call will also be available on Teva’s website at: www.tevapharm.com, under Investor Relations Events and Presentations. Please log in at least 10 minutes prior to the conference call in order to download the applicable audio software.

Teva Pharmaceutidustries Ltd. is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients.

**************************

http://pennyomega.com/img/mjgcf.jpgMajestic Gold Corp. (MJGCF.PK)

Majestic Gold Corp. engages in the exploration and development of mineral properties in China. The company focuses on its gold project located in the prolific gold region of Song Jiagou in eastern Shandong Province. Majestic Gold Corp. is headquartered in Vancouver, Canada.

Gold facts about jewelry include the following. The Ancient Egyptians were the first to use gold to create jewelry. Gold mines produce gold commercially on every continent except Antarctica. Gold is the only precious metal that is yellow in color. Generally, pure gold is too soft and delicate to be used for jewelry, and must be alloyed with other metals to create a metal strong enough to be durable against wear and tear. Gold is the most common and popular precious metal used for wedding rings. Gold is the only known metal that is impervious to rusting.

Majestic Gold Corp. (MJGCF.PK) has arranged a $10,000,000 loan to advance its Song Jiagou project in China. Nine million dollars ($9,000,000) from the proceeds from the loan will be used by the Company to in connection with its Song Jiagou project and the balance of one million dollars ($1,000,000) for general working capital purposes.

The loan will have a one year term and loan principal will be convertible at the option of the lender in whole or in part into common shares (”Shares”) of the Company until twelve months from the date of the loan advance at the price of $0.205 per Share. The loan will bear interest at the rate of 7.5% per annum, payable on maturity, and accrued and unpaid interest will be convertible at the option of the lender in whole or in part into shares of the Company until twelve months from the date of the loan advance at Market Price at the time of conversion.

The lender is at arm’s length from the Company and will not become an insider as a result of any conversion of principal and interest. All shares issued on any conversion of loan principal or interest will be subject to a four month hold period from the date of advance of loan proceeds. The loan is subject to acceptance by the TSX Venture Exchange.

As additional consideration for the loan, the Company has agreed to forward at least $9 million to Majestic Yantai Gold Ltd., a British Virgin Islands company owned 94% by the Company to be used to further advance its Song Jiagou project. The Borrower has also agreed to a 90 day period for reciprocal due diligence reviews and discussions for the possible further involvement of the Lender in the Song Jiagou project.

In the event that no further agreement is reached between the Lender and the Company during the 90 day period, then the loan and a minimum of seven (7) months interest will automatically convert to shares in the Company at a price of $0.205 per share and the interest at Market Price respectively. In addition the Company is pleased to announce that it has arranged a non-brokered private placement of up to 15,000,000 shares to be issued at the price of $0.20 per share for gross proceeds of $3,000,000.

For more information about company: www.majesticgold.net

**************************

Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR) and Astellas Pharma Europe Ltd., a European subsidiary of Tokyo -based Astellas Pharma Inc. announced that the European Commission has granted Marketing Authorization (MA) for DIFICLIR ™ (fidaxomicin) tablets for the treatment of adults with Clostridium difficile infections (CDI) also known as Clostridium difficile-associated diarrhea (CDAD). CDI is a significant problem in hospitals and long-term care facilities all over the world. EMA approval was based on two large, multi-national, Phase 3 clinical trials that demonstrated that DIFICLIR was as effective as oral vancomycin in treating CDI.

Optimer Pharmaceuticals, Inc. is a global biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society.

**************************

Stereotaxis, Inc. (NASDAQ:STXS) announced that the Company has started initial shipments of the Epoch platform, its comprehensive solution for the electrophysiology (EP) lab that is designed to increase efficiency in procedures with a fully-remote, networked robotic and magnetic navigation system. Initial shipments include system upgrades to the new generation Epoch platform from the Niobe® II navigation system for customers in North America and Europe.

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital’s interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias.

**************************************************************

drstbc

**************************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

 
Share/Bookmark
 
 
 

PDLI, AMGN, TEVA - Stocks updates at NASDAQ Healthcare Sector by DrStockPick.com

Thursday, March 3rd, 2011

PDL BioPharma Inc. (NASDAQ:PDLI) increased 3.75% to close at $5.81. PDLI traded 5.76 million shares for the day and its earning per share remained $0.85. PDL BioPharma, Inc. engages in the management of antibody humanization patents and royalty assets, which consist of Queen et al. patents and license agreements with various biotechnology and pharmaceutical companies. Its Queen et al. patents primarily cover humanized antibodies, methods for humanizing antibodies, polynucleotide encoding in humanized antibodies, and methods of producing humanized antibodies. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.

Amgen, Inc. (NASDAQ:AMGN) decreased 1.00% to close at $51.39. AMGN traded 5.44 million shares for the day and its earning per share remained $4.79. Amgen Inc., a biotechnology medicines company, discovers, develops, manufactures, and delivers human therapeutics based on advances in cellular and molecular biology primarily in the United States, Europe, and Canada. The company markets primarily recombinant protein therapeutics in supportive cancer care, nephrology, and inflammation. Its principal products include Aranesp and EPOGEN erythropoietic-stimulating agents that stimulate the production of red blood cells.

Teva Pharmaceutical Industries Ltd (ADR) (NASDAQ:TEVA) increased 1.78% to close at $50.82. TEVA traded 4.79 million shares for the day and its earning per share remained $3.66. Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, produces, and markets generic drugs in various therapeutic categories worldwide. It offers generic pharmaceutical products in a range of dosage forms, such as tablets, capsules, ointments, creams, liquids, injectables, and inhalants. The company also provides branded products, including Copaxone to treat multiple sclerosis; and Azilect to treat Parkinson’s disease. The company was founded in 1901 and is headquartered in Petach Tikva, Israel.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

 
Share/Bookmark
 
 
 

TEVA, AMGN, ARIA – Hot Stocks at NASDAQ Healthcare Sector by DrStockPick.com

Tuesday, December 7th, 2010

Teva Pharmaceutical Industries Ltd (ADR) (NASDAQ:TEVA) decreased 0.34% to close at $49.11. TEVA traded 6.25 million shares for the day and its earning per share remained $3.25. Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical company that develops, produces and markets generic drugs covering all treatment categories. The Company has a pharmaceutical business, whose principal products are Copaxone for multiple sclerosis and Azilect for Parkinson’s disease, respiratory products and women’s health products. On January 29, 2009, the Company sold its Israeli animal health product line to Phibro Animal Health Corporation.

Amgen, Inc. (NASDAQ:AMGN) decreased 0.61% to close at $53.40. AMGN traded 4.07 million shares for the day and its earning per share remained $4.63. Amgen Inc. (Amgen) is an independent biotechnology medicines company. The Company discovers, develops, manufactures and markets medicines for grievous illnesses. It focuses on human therapeutics and concentrates on medicines based on advances in cellular and molecular biology. Its principal products include Aranesp (darbepoetin alfa) and EPOGEN (Epoetin alfa), erythropoietic-stimulating agents (ESAs) that stimulate the production of red blood cells; an inhibitor of tumor necrosis factor (TNF), a substance that plays a role in the body’s response to inflammatory diseases.

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) increased 7.07% to close at $4.39. ARIA traded 2.61 million shares for the day and its earning per share remained $0.88. ARIAD Pharmaceuticals, Inc. (ARIAD) is a biopharmaceutical company focused on the discovery and development of drugs to provide therapeutic intervention in treating human diseases at the cellular level. The Company’s lead cancer product candidate, ridaforolimus, is an internally discovered, potent inhibitor of the protein mTOR. Its third product candidate, AP26113, is an investigational anaplastic lymphoma kinase (ALK), including non-small cell lung cancer, lymphoma and neuroblastoma.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

 
Share/Bookmark
 
 
 

DrStockPick.com Reports The Latest News From Medical Companies PROT, CYCC and TEVA.

Saturday, August 7th, 2010

drstock-2-3

signup3m

 

 

**************************************************************

 

 

PROTEONOMIX, INC. (PROT.OB), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, applauds the actions taken by the Costa Rican Ministry of Health to crack down on unauthorized stem cell clinics. The chief of the ministry’s research council, Dr. Ileana Herrera, stated, “If (stem cell treatment’s) efficacy and safety has not been proven, we don’t believe it should be used.”

Mr. Michael Cohen, Chairman and CEO of Proteonomix, stated, “We have no doubt that stem cell therapies will be a major factor in combatting a variety of medical conditions but it is essential that it be undertaken only after the clinical results determine that such a course of action is efficacious. Too much hype about cures for all types of diseases is diminishing the potential value of stem cells and could unduly delay future progress in stem cell treatments and research. Medical tourism is not a dirty word, if established in an ethical and professional manner.”

Cohen added, “At Proteonomix we have adopted a rigorous and cautious approach that will ensure that patients that are ultimately treated by us have confidence that the procedures will be safe, relatively low cost and offering the best chance for alleviating their specific medical condition. Our research progress has been dramatic and the procedures and intellectual property portfolio, made up of a significant number of pending patents, have resulted in Proteonomix emerging as a leader in the development of stem cell medical treatments.”

“The mission of one of our subsidiaries, Proteonomix Regenerative Translational Medicine Institute, Inc. (’PRTMI’), is to translate the most promising internal and external stem cell biology and cellular therapy to clinical applications of regenerative medicine. PRTMI will undertake the creation of a global, single standard, cellular laboratory that will seek to create a seamless transition between laboratories and patient care facilities.”

Mr. Cohen concluded, “We view joint ventures with appropriate strategic partners as a key to the success of Proteonomix and, at the appropriate time, anticipate that PRTMI will engage in such discussions.”

 

Cyclacel Logo with link to Home page

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC), is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders. Three product candidates are in clinical development:

Sapacitabine (CYC682), a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and lung cancer.

Seliciclib (CYC202 or R-roscovitine), a CDK (cyclin dependent kinase) inhibitor, is in Phase 2 studies for the treatment of lung cancer and nasopharyngeal cancer and in a Phase 1 trial in combination with sapacitabine.

CYC116, an Aurora kinase and VEGFR2 inhibitor, is in a Phase 1 trial in patients with solid tumors.

Cyclacel’s ALIGN Pharmaceuticals subsidiary markets directly in the U.S., Xclair® Cream for radiation dermatitis, Numoisyn® Liquid and Numoisyn® Lozenges for xerostomia. Cyclacel’s strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a portfolio of commercial products and a development pipeline of novel drug candidates.

 

Teva

Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) commented recently on the U.S. Food and Drug Administration’s response to a citizen petition questioning the approval criteria for a generic Lovenox® (enoxaparin sodium) injection and its subsequent approval of another generic filer’s Abbreviated New Drug Application (ANDA).

After reviewing the FDA’s response to the citizen petition, which outlines 5 criteria to demonstrate “sameness”, Teva believes that it has demonstrated to the FDA that its version of generic Lovenox meets their criteria and that Teva’s pending ANDA is approvable.

Teva maintains the approval for an ANDA for generic Lovenox is appropriate because:
- The active ingredient in enoxaparin is significantly better characterized than the active ingredients of significantly more complex molecules
- Pharmacologically active portions of enoxaparin can be identified and replicated, and
- In vitro and in vivo PD tests are rapidly indicative of drug efficacy and safety

Teva recognizes and supports FDA authority and discretion to make generic drug approvals on a case-by-case basis considering drug complexity, patient efficacy and safety outcomes.

Given the complexity of Teva’s Copaxone® and the serious, degenerative nature of multiple sclerosis, it is Teva’s belief that any potential generic version of Copaxone should be evaluated via pre-clinical and full-scale, placebo-controlled clinical trials with measured clinical endpoints in multiple sclerosis patients to establish safety, efficacy and immunogenicity in a real patient population.

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 15 pharmaceutical companies in the world and is the leading generic pharmaceutical company. The company develops, manufactures and markets generic and innovative pharmaceuticals and active pharmaceutical ingredients. Over 80 percent of Teva’s sales are in North America and Western Europe.

**************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

 

drstbc

 

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer ) . Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading shares from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB)

 
Share/Bookmark
 
 
 

PWRM.OB, NASDAQ:TEVA, MDHI.OB Dr. Stock Pick’s News From Medical Companies.

Tuesday, July 27th, 2010

drstock-2-3

signup3m

 

 

**************************************************************

power3

Power3 Medical Products, Inc. (OTCBB: PWRM) announced that, in collaboration with Lourdes R. Bosquez, MD, it has unexpectedly discovered new and unprecedented findings regarding clinically important differences in the response of the NuroPro® protein biomarkers in the blood of untreated Alzheimer’s disease patients compared to patients treated with the widely used anti-dementia drugs Aricept® (Donepezil HCl, Pfizer – NYSE: PFE), Exelon® (Rivastigmine, Novartis – NYSE: NVS), and Namenda® (Memantine HCl, Forest Laboratories – NYSE: FRX). These results relate to the genetically distinct groups of Alzheimer’s disease patients, i.e., those individuals who possess the Alzheimer’s high-risk gene for Apolipoprotein E4 and those who do not possess the gene.

NuroPro® was originally indicated for diagnostics to determine whether or not a patient had Alzheimer’s disease. With these results, NuroPro® now extends into the pharmaceutical arena due to its ability to predict and monitor the response to drug treatment, including the underlying disease process and the insidious progression of irreversible neurological damage, even in the face of temporary improvements in cognition and other symptoms.

Power3 has filed for patent protection for these findings and will be publishing these seminal results in the near future in one of the world’s most prestigious peer-reviewed scientific journals. Power3 also plans to demonstrate the clinical application and benefits of its NuroPro® diagnostic tests to healthcare providers located throughout the world. Power3 believes that this will assist the company greatly in an effort to generate sales of its NuroPro® diagnostic tests. Power3 is currently working on a joint distribution effort with a number of potential business partners, such as the companies mentioned above, for the sale of its NuroPro® diagnostic tests and the development of new drugs.

“This new and amazing discovery will help clarify some of the clinical observations and overcome difficulties that we have had as physicians, not only by helping us choose more appropriate treatment and better predict response, but also by helping us find more permanent treatments for the dementias,” said Dr. Bosquez.

Ira L. Goldknopf, Ph.D., President and Chief Scientific Officer of Power3, stated, “This innovation will provide physicians with an invaluable perspective to use in the treatment of their patients and will have profound implications for the diagnosis and treatment of Alzheimer’s disease, and for other diseases as well.”

Teva

 

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) commented recently on the U.S. Food and Drug Administration’s response to a citizen petition questioning the approval criteria for a generic Lovenox® (enoxaparin sodium) injection and its subsequent approval of another generic filer’s Abbreviated New Drug Application (ANDA).

After reviewing the FDA’s response to the citizen petition, which outlines 5 criteria to demonstrate “sameness”, Teva believes that it has demonstrated to the FDA that its version of generic Lovenox meets their criteria and that Teva’s pending ANDA is approvable.

Teva maintains the approval for an ANDA for generic Lovenox is appropriate because:
- The active ingredient in enoxaparin is significantly better characterized than the active ingredients of significantly more complex molecules
- Pharmacologically active portions of enoxaparin can be identified and replicated, and
- In vitro and in vivo PD tests are rapidly indicative of drug efficacy and safety

Teva recognizes and supports FDA authority and discretion to make generic drug approvals on a case-by-case basis considering drug complexity, patient efficacy and safety outcomes.

Given the complexity of Teva’s Copaxone® and the serious, degenerative nature of multiple sclerosis, it is Teva’s belief that any potential generic version of Copaxone should be evaluated via pre-clinical and full-scale, placebo-controlled clinical trials with measured clinical endpoints in multiple sclerosis patients to establish safety, efficacy and immunogenicity in a real patient population.

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 15 pharmaceutical companies in the world and is the leading generic pharmaceutical company. The company develops, manufactures and markets generic and innovative pharmaceuticals and active pharmaceutical ingredients. Over 80 percent of Teva’s sales are in North America and Western Europe.

 

medical-alarm_logo

Medical Alarm Concepts Holding, Inc. (OTCBB:MDHI), manufacturer of the MediPendant™, the first fully-monitored medical alarm system that allows you to speak and listen directly through the pendant, announces the availability of a new video interview with the Company’s CEO Howard Teicher. The video also includes a demonstration of the superior features, functions and benefits of the revolutionary MediPendant.

“We are extremely excited about the potential of the MediPendant. I encourage everyone to watch the video, which provides a strong understanding of why we believe our personal alarm system is superior to anything on the market today. It is very powerful, user-friendly and gives the customers the freedom and peace of mind to be able to communicate in a two-way manner through the pendant with an EMT-certified operator anytime and anywhere within a 600 feet radius of the home base station. No other system offers this capability. We are very optimistic about our future as we continue to expand our distribution partnerships,” said Howard Teicher, CEO of Medical Alarm Concepts.

Medical Alarm Concepts Holdings, Inc. develops and manufactures innovative products and practical solutions within the framework of a vast growing marketplace. Medical Alarm Concepts has built their reputation in the personal emergency response system (”PERS”) and medical alert industry. With patented technology and state-of-the-art services, MAC is uniquely positioned to mobilize the right people, skills and alliances to ensure success and client satisfaction. Medical Alarm Concepts design and support philosophy emphasizes industry best practices, while providing polished and savvy solutions. MAC’s latest innovation is the development of its two-way voice speakerphone pendant technology.

 

 

 

**************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

 

drstbc

 

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer ) . Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB)

 
Share/Bookmark
 
 
 
  • Site Translator:
Exclusive Videos










Hot stocks to watch!

Petroleo Brasileiro SA - PBR

News Corp - NWSA

AT&T Inc - T

Cleantech Transit, Inc. - CLNO.OB

Tellabs, Inc - TLAB

Marshall & Ilsley Corp - MI

Oracle Corporation - ORCL

Isilon Systems Inc - ISLN

iShares Down Jones U.S. Real Estate Index - IYR

Citigroup Inc - C

Crown Equity Holdings Inc. - CRWE.OB

SPDR Gold Trust ETF - GLD

Bucyrus International Inc - BUCY

iShares MSCI Emerging Markets Index ETF - EEM

SanDisk Crop - SNDK

Direxion Shs Etf Tr - FAZ

Comcast Corp New - CMCSA

PowerShares QQQ - QQQQ

Baidu Inc - BIDU

iShares MSCI EAFE Index ETF - EFA

Wal-Mart Stores Inc - WMT

Intel Corporation - INTC

 
 
Live With Dr.StockPick
Coming Soon
 
 
DrStockPick.com Newsletter
hot penny stocks, stock picks

 

Follow Dr Stock Pick at
PennyOmega.com Vision

Every success must begin with a vision. If you can see it, you can achieve it.